As the first-to-market DPP-1 inhibitor, Brinsupri is on course to become the standard of care in bronchiectasis treatment.
Since Brinsupri’s approval, Insmed has been at the forefront of non-cystic fibrosis bronchiectasis (NCFB), supporting programs to increase disease awareness and to improve clinical outcomes in this disease space. Credit: [U.P.SD]/Shutterstock.com
At the 2026 American Thoracic Society (ATS) international conference, Insmed’s presence featured a strong focus on Brinsupri (brensocatib), the first-to-market therapy for non-cystic fibrosis bronchiectasis (NCFB) and first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor targeting neutrophilic inflammation. Insmed’s ATS presence was wide and coordinated; it included poster sessions pertaining to Brinsupri and its impact on patient-reported respiratory symptoms in NCFB, survey results highlighting NCFB disease burden, a well-engaged industry theatre session focused on the new therapy, and significant on-ground presence. Combined with Insmed’s recent support of a landmark ATS initiative, the company’s ongoing efforts will continue to strengthen Brinsupri’s clinical profile and drive its adoption as it navigates the NCFB treatment landscape as the first-to-market therapy following its FDA approval in August 2025.
